<br>        Inclusion Criteria:<br><br>          -  Men and women = 18 years of age<br><br>          -  ECOG performance status of = 2<br><br>          -  Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1<br>             or t(11;14), and measurable disease on cross sectional imaging that is = 2 cm in the<br>             longest diameter and measurable in 2 perpendicular dimensions<br><br>          -  Documented failure to achieve at least partial response (PR) with, or documented<br>             disease progression disease after, the most recent treatment regimen<br><br>          -  At least 1, but no more than 5, prior treatment regimens for MCL (Note: Subjects<br>             having received =2 cycles of prior treatment with bortezomib, either as a single agent<br>             or as part of a combination therapy regimen, will be considered to be<br>             bortezomib-exposed.)<br><br>          -  Willing and able to participate in all required evaluations and procedures in this<br>             study protocol including swallowing capsules without difficulty<br><br>          -  Ability to understand the purpose and risks of the study and provide signed and dated<br>             informed consent and authorization to use protected health information (in accordance<br>             with national and local subject privacy regulations)<br><br>        Major exclusion criteria:<br><br>          -  Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer<br>             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation<br>             therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drug<br><br>          -  Any life-threatening illness, medical condition or organ system dysfunction which, in<br>             the investigator's opinion, could compromise the subject's safety, interfere with the<br>             absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue<br>             risk<br><br>          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic<br>             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of<br>             screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart<br>             Association Functional Classification<br><br>          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or<br>             resection of the stomach or small bowel or ulcerative colitis, symptomatic<br>             inflammatory bowel disease, or partial or complete bowel obstruction<br><br>          -  Any of the following laboratory abnormalities:<br><br>               1. Absolute neutrophil count (ANC) < 750 cells/mm3 (0.75 x 109/L) unless there is<br>                  documented bone marrow involvement<br><br>               2. Platelet count < 50,000 cells/mm3 (50 x 109/L) independent of transfusion support<br>                  unless there is documented bone marrow involvement<br><br>               3. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) = 3.0<br>                  x upper limit of normal (ULN)<br><br>               4. Creatinine > 2.0 x ULN<br>      ;<br>        Inclusion Criteria:<br><br>          -  Men and women = 18 years of age<br><br>          -  ECOG performance status of = 2<br><br>          -  Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1<br>             or t(11;14), and measurable disease on cross sectional imaging that is = 2 cm in the<br>             longest diameter and measurable in 2 perpendicular dimensions<br><br>          -  Documented failure to achieve at least partial response (PR) with, or documented<br>             disease progression disease after, the most recent treatment regimen<br><br>          -  At least 1, but no more than 5, prior treatment regimens for MCL (Note: Subjects<br>             having received =2 cycles of prior treatment with bortezomib, either as a single agent<br>             or as part of a combination therapy regimen, will be considered to be<br>             bortezomib-exposed.)<br><br>          -  Willing and able to participate in all required evaluations and procedures in this<br>             study protocol including swallowing capsules without difficulty<br><br>          -  Ability to understand the purpose and risks of the study and provide signed and dated<br>             informed consent and authorization to use protected health information (in accordance<br>             with national and local subject privacy regulations)<br><br>        Major exclusion criteria:<br><br>          -  Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer<br>             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation<br>             therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drug<br><br>          -  Any life-threatening illness, medical condition or organ system dysfunction which, in<br>             the investigator's opinion, could compromise the subject's safety, interfere with the<br>             absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue<br>             risk<br><br>          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic<br>             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of<br>             screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart<br>             Association Functional Classification<br><br>          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or<br>             resection of the stomach or small bowel or ulcerative colitis, symptomatic<br>             inflammatory bowel disease, or partial or complete bowel obstruction<br><br>          -  Any of the following laboratory abnormalities:<br><br>               1. Absolute neutrophil count (ANC) < 750 cells/mm3 (0.75 x 109/L) unless there is<br>                  documented bone marrow involvement<br><br>               2. Platelet count < 50,000 cells/mm3 (50 x 109/L) independent of transfusion support<br>                  unless there is documented bone marrow involvement<br><br>               3. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) = 3.0<br>                  x upper limit of normal (ULN)<br><br>               4. Creatinine > 2.0 x ULN<br>      ;<br>        Inclusion Criteria:<br><br>          -  Men and women = 18 years of age<br><br>          -  ECOG performance status of = 2<br><br>          -  Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1<br>             or t(11;14), and measurable disease on cross sectional imaging that is = 2 cm in the<br>             longest diameter and measurable in 2 perpendicular dimensions<br><br>          -  Documented failure to achieve at least partial response (PR) with, or documented<br>             disease progression disease after, the most recent treatment regimen<br><br>          -  At least 1, but no more than 5, prior treatment regimens for MCL (Note: Subjects<br>             having received =2 cycles of prior treatment with bortezomib, either as a single agent<br>             or as part of a combination therapy regimen, will be considered to be<br>             bortezomib-exposed.)<br><br>          -  Willing and able to participate in all required evaluations and procedures in this<br>             study protocol including swallowing capsules without difficulty<br><br>          -  Ability to understand the purpose and risks of the study and provide signed and dated<br>             informed consent and authorization to use protected health information (in accordance<br>             with national and local subject privacy regulations)<br><br>        Major exclusion criteria:<br><br>          -  Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer<br>             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation<br>             therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drug<br><br>          -  Any life-threatening illness, medical condition or organ system dysfunction which, in<br>             the investigator's opinion, could compromise the subject's safety, interfere with the<br>             absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue<br>             risk<br><br>          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic<br>             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of<br>             screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart<br>             Association Functional Classification<br><br>          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or<br>             resection of the stomach or small bowel or ulcerative colitis, symptomatic<br>             inflammatory bowel disease, or partial or complete bowel obstruction<br><br>          -  Any of the following laboratory abnormalities:<br><br>               1. Absolute neutrophil count (ANC) < 750 cells/mm3 (0.75 x 109/L) unless there is<br>                  documented bone marrow involvement<br><br>               2. Platelet count < 50,000 cells/mm3 (50 x 109/L) independent of transfusion support<br>                  unless there is documented bone marrow involvement<br><br>               3. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) = 3.0<br>                  x upper limit of normal (ULN)<br><br>               4. Creatinine > 2.0 x ULN<br>      ;<br>        Inclusion Criteria:<br><br>          -  Men and women = 18 years of age<br><br>          -  ECOG performance status of = 2<br><br>          -  Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1<br>             or t(11;14), and measurable disease on cross sectional imaging that is = 2 cm in the<br>             longest diameter and measurable in 2 perpendicular dimensions<br><br>          -  Documented failure to achieve at least partial response (PR) with, or documented<br>             disease progression disease after, the most recent treatment regimen<br><br>          -  At least 1, but no more than 5, prior treatment regimens for MCL (Note: Subjects<br>             having received =2 cycles of prior treatment with bortezomib, either as a single agent<br>             or as part of a combination therapy regimen, will be considered to be<br>             bortezomib-exposed.)<br><br>          -  Willing and able to participate in all required evaluations and procedures in this<br>             study protocol including swallowing capsules without difficulty<br><br>          -  Ability to understand the purpose and risks of the study and provide signed and dated<br>             informed consent and authorization to use protected health information (in accordance<br>             with national and local subject privacy regulations)<br><br>        Major exclusion criteria:<br><br>          -  Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer<br>             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation<br>             therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drug<br><br>          -  Any life-threatening illness, medical condition or organ system dysfunction which, in<br>             the investigator's opinion, could compromise the subject's safety, interfere with the<br>             absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue<br>             risk<br><br>          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic<br>             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of<br>             screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart<br>             Association Functional Classification<br><br>          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or<br>             resection of the stomach or small bowel or ulcerative colitis, symptomatic<br>             inflammatory bowel disease, or partial or complete bowel obstruction<br><br>          -  Any of the following laboratory abnormalities:<br><br>               1. Absolute neutrophil count (ANC) < 750 cells/mm3 (0.75 x 109/L) unless there is<br>                  documented bone marrow involvement<br><br>               2. Platelet count < 50,000 cells/mm3 (50 x 109/L) independent of transfusion support<br>                  unless there is documented bone marrow involvement<br><br>               3. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) = 3.0<br>                  x upper limit of normal (ULN)<br><br>               4. Creatinine > 2.0 x ULN<br>